MoonLake ImmunotherapeuticsMLTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank80
3Y CAGR+63.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+63.2%/yr
Annual compound
Percentile
P80
Within normal range
vs 3Y Ago
4.3x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 79.89% |
| 2024 | 254.61% |
| 2023 | -24.37% |
| 2022 | 18.37% |
| 2021 | 0.00% |
| 2020 | 0.00% |